Chemomab Therapeutics Ltd. SEC filings CMMB
Chemomab Therapeutics Ltd. has 366 filings in SEC EDGAR's recent list, going back to Nov 7, 2011. Its latest annual report, Form 20-F, was filed on Mar 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on May 11, 2023, covering the quarter ended Mar 31, 2023. The most recent current report (Form 6-K) was filed on Nov 3, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Nov 3, 2026 | Nov 3, 2026 |
| 6-K | Current report (foreign issuer) | Oct 19, 2026 | Oct 19, 2026 |
| 6-K | Current report (foreign issuer) | Sep 30, 2026 | Sep 30, 2026 |
| 6-K | Current report (foreign issuer) | Aug 19, 2026 | Jun 30, 2026 |
| 6-K | Current report (foreign issuer) | Jul 8, 2026 | Jul 8, 2026 |
| 6-K | Current report (foreign issuer) | Jun 2, 2026 | Jun 2, 2026 |
| 6-K | Current report (foreign issuer) | May 14, 2026 | May 14, 2026 |
| 6-K | Current report (foreign issuer) | May 6, 2026 | May 6, 2026 |
| 6-K | Current report (foreign issuer) | Apr 28, 2026 | Apr 28, 2026 |
| 6-K | Current report (foreign issuer) | Mar 20, 2026 | Mar 20, 2026 |
| 6-K | Current report (foreign issuer) | Mar 19, 2026 | Mar 19, 2026 |
| 6-K | Current report (foreign issuer) | Nov 21, 2025 | Nov 21, 2025 |
| 6-K | Current report (foreign issuer) | Aug 22, 2025 | Aug 22, 2025 |
| 6-K | Current report (foreign issuer) | Aug 14, 2025 | Jun 30, 2025 |
| 6-K | Current report (foreign issuer) | Jul 25, 2025 | Jul 25, 2025 |
| 6-K | Current report (foreign issuer) | Jul 1, 2025 | Jul 1, 2025 |
| 6-K | Current report (foreign issuer) | May 27, 2025 | May 27, 2025 |
| 6-K | Current report (foreign issuer) | May 15, 2025 | May 15, 2025 |
| 6-K | Current report (foreign issuer) | Apr 15, 2025 | Apr 15, 2025 |
| 6-K | Current report (foreign issuer) | Mar 27, 2025 | Mar 27, 2025 |
| 6-K | Current report (foreign issuer) | Mar 20, 2025 | Mar 20, 2025 |
| 6-K | Current report (foreign issuer) | Mar 3, 2025 | Mar 3, 2025 |
| 6-K | Current report (foreign issuer) | Feb 19, 2025 | Feb 19, 2025 |
| 6-K | Current report (foreign issuer) | Nov 18, 2024 | Nov 18, 2024 |
| 6-K | Current report (foreign issuer) | Nov 14, 2024 | Nov 14, 2024 |
| 6-K | Current report (foreign issuer) | Oct 11, 2024 | Oct 11, 2024 |
| 6-K | Current report (foreign issuer) | Aug 21, 2024 | Jun 30, 2024 |
| 6-K | Current report (foreign issuer) | Jul 25, 2024 | Jul 25, 2024 |
| 6-K | Current report (foreign issuer) | Jun 12, 2024 | Jun 12, 2024 |
| 6-K | Current report (foreign issuer) | May 9, 2024 | May 9, 2024 |
| 6-K | Current report (foreign issuer) | May 8, 2024 | May 8, 2024 |
| 6-K | Current report (foreign issuer) | May 3, 2024 | May 3, 2024 |
| 6-K | Current report (foreign issuer) | Mar 7, 2024 | Mar 7, 2024 |
| 6-K | Current report (foreign issuer) | Jan 3, 2024 | Jan 3, 2024 |
| 6-K | Current report (foreign issuer) | Nov 9, 2023 | Nov 9, 2023 |
| 6-K | Current report (foreign issuer) | Aug 14, 2023 | Jun 30, 2023 |
| 6-K | Current report (foreign issuer) | Aug 8, 2023 | Aug 8, 2023 |
| 6-K | Current report (foreign issuer) | Jul 3, 2023 | Jul 3, 2023 |
| 8-K |
Current report
Officer or director change
|
Jun 16, 2023 | Jun 14, 2023 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jun 5, 2023 | Jun 1, 2023 |
| 8-K |
Current report
Results of operations
|
May 11, 2023 | May 11, 2023 |
| 8-K |
Current report
Other events
|
Feb 21, 2023 | Feb 21, 2023 |
| 8-K |
Current report
Results of operations
|
Feb 21, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 11, 2023 | Jan 11, 2023 |
| 8-K |
Current report
Other events
|
Jan 3, 2023 | Jan 3, 2023 |
| 8-K/A | Amended current report | Nov 29, 2022 | Nov 14, 2022 |
| 8-K |
Current report
Other events
|
Nov 16, 2022 | Nov 16, 2022 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Nov 14, 2022 | Nov 14, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2022 | Aug 12, 2022 |
| 8-K | Current report | Jun 21, 2022 | Jun 21, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 8, 2022 | Jun 8, 2022 |
| 8-K |
Current report
Officer or director change
|
Jun 1, 2022 | Jun 1, 2022 |
| 8-K |
Current report
Results of operations
|
May 12, 2022 | May 12, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 9, 2022 | Mar 9, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Feb 11, 2022 | Feb 11, 2022 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Dec 16, 2021 | Dec 16, 2021 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Dec 3, 2021 | Dec 3, 2021 |
| 8-K/A |
Amended current report
Officer or director change, Regulation FD disclosure
|
Nov 12, 2021 | Nov 12, 2021 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2021 | Nov 12, 2021 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 10, 2021 | Nov 10, 2021 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Nov 8, 2021 | Nov 8, 2021 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 3, 2021 | Nov 3, 2021 |
| 8-K |
Current report
Shareholder vote results
|
Oct 26, 2021 | Oct 26, 2021 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 25, 2021 | Oct 25, 2021 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 2, 2021 | Sep 2, 2021 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2021 | Aug 13, 2021 |
| 8-K |
Current report
Shareholder vote results
|
Jul 22, 2021 | Jul 22, 2021 |
| 8-K |
Current report
Results of operations
|
May 13, 2021 | May 13, 2021 |
| 8-K/A | Amended current report | Apr 14, 2021 | Mar 15, 2021 |
| 8-K |
Current report
Other events
|
Apr 5, 2021 | Apr 5, 2021 |
| 8-K/A | Amended current report | Mar 19, 2021 | Mar 15, 2021 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Change to shareholder rights, Change in control, Officer or director change, Bylaw or fiscal year change, Shareholder vote results
|
Mar 17, 2021 | Mar 15, 2021 |
| 8-K |
Current report
Other events
|
Mar 10, 2021 | Mar 9, 2021 |
| 8-K |
Current report
Other events
|
Feb 8, 2021 | Feb 8, 2021 |
| 8-K |
Current report
Material agreement, Other events
|
Dec 15, 2020 | Dec 14, 2020 |
| 8-K |
Current report
Officer or director change
|
Oct 20, 2020 | Oct 20, 2020 |
| 8-K |
Current report
Officer or director change
|
Jul 15, 2020 | Jul 15, 2020 |
| 8-K |
Current report
Officer or director change, Other events
|
Jul 9, 2020 | Jul 9, 2020 |
| 8-K |
Current report
Officer or director change
|
May 21, 2020 | May 21, 2020 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
May 6, 2020 | May 5, 2020 |
| 8-K |
Current report
Shareholder vote results
|
Apr 24, 2020 | Apr 24, 2020 |
| 8-K |
Current report
Listing notice
|
Apr 15, 2020 | Apr 15, 2020 |
| 8-K |
Current report
Other events
|
Mar 16, 2020 | Mar 16, 2020 |
| 8-K |
Current report
Officer or director change, Other events
|
Feb 10, 2020 | Feb 10, 2020 |
| 8-K |
Current report
Exit or restructuring costs, Regulation FD disclosure
|
Feb 4, 2020 | Feb 3, 2020 |
| 8-K |
Current report
Other events
|
Jan 31, 2020 | Jan 31, 2020 |
| 8-K |
Current report
Other events
|
Jan 10, 2020 | Jan 9, 2020 |
| 8-K |
Current report
Officer or director change, Other events
|
Jan 2, 2020 | Jan 2, 2020 |
| 6-K | Current report (foreign issuer) | Nov 21, 2019 | Nov 21, 2019 |
| 6-K | Current report (foreign issuer) | Nov 15, 2019 | Nov 15, 2019 |
| 6-K | Current report (foreign issuer) | Nov 12, 2019 | Nov 12, 2019 |
| 6-K | Current report (foreign issuer) | Oct 28, 2019 | Oct 28, 2019 |
| 6-K | Current report (foreign issuer) | Sep 23, 2019 | Sep 23, 2019 |
| 6-K | Current report (foreign issuer) | Aug 13, 2019 | Aug 13, 2019 |
| 6-K | Current report (foreign issuer) | Aug 6, 2019 | Aug 5, 2019 |
| 6-K | Current report (foreign issuer) | Jul 8, 2019 | Jul 8, 2019 |
| 6-K | Current report (foreign issuer) | Jun 18, 2019 | Jun 18, 2019 |
| 6-K | Current report (foreign issuer) | May 28, 2019 | May 28, 2019 |
| 6-K | Current report (foreign issuer) | May 22, 2019 | May 22, 2019 |
| 6-K | Current report (foreign issuer) | Mar 14, 2019 | Mar 14, 2019 |
| 6-K | Current report (foreign issuer) | Mar 12, 2019 | Mar 12, 2019 |
| 6-K | Current report (foreign issuer) | Feb 14, 2019 | Feb 14, 2019 |
| 6-K | Current report (foreign issuer) | Feb 12, 2019 | Feb 12, 2019 |
| 6-K | Current report (foreign issuer) | Dec 26, 2012 | Dec 26, 2012 |
| 6-K | Current report (foreign issuer) | Dec 17, 2012 | Dec 17, 2012 |
| 6-K | Current report (foreign issuer) | Nov 27, 2012 | Nov 27, 2012 |
| 6-K | Current report (foreign issuer) | Nov 14, 2012 | Nov 14, 2012 |
| 6-K | Current report (foreign issuer) | Nov 5, 2012 | Nov 5, 2012 |
| 6-K | Current report (foreign issuer) | Oct 22, 2012 | Oct 22, 2012 |
| 6-K | Current report (foreign issuer) | Oct 2, 2012 | Oct 2, 2012 |
| 6-K | Current report (foreign issuer) | Oct 1, 2012 | Oct 1, 2012 |
| 6-K | Current report (foreign issuer) | Sep 4, 2012 | Sep 4, 2012 |
| 6-K | Current report (foreign issuer) | Aug 20, 2012 | Aug 20, 2012 |
| 6-K | Current report (foreign issuer) | Aug 13, 2012 | Aug 13, 2012 |
| 6-K | Current report (foreign issuer) | Aug 9, 2012 | Aug 9, 2012 |
| 6-K | Current report (foreign issuer) | Jul 23, 2012 | Jul 23, 2012 |
Showing 116 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CMMB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Tel Aviv
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1534248
- Former names
- Anchiano Therapeutics Ltd. (until Mar 17, 2021); BioCancell Ltd. (until Nov 3, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.